Perez, Edith A <br/><br/>
Cardiac toxicity of ErbB2-targeted therapies: what do we know?  [electronic resource] 

 -  Clinical breast cancer  Mar 2008 
 - S114-20 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1526-8209 
<br/><br/><label>Standard No.: </label>10.3816/cbc.2008.s.007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Breast Neoplasms--drug therapy<br/>Clinical Trials as Topic<br/>Female<br/>Heart--drug effects<br/>Heart Failure--chemically induced<br/>Humans<br/>Lapatinib<br/>Quinazolines--adverse effects<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Trastuzumab